An innovative and surprising therapy in Parkinson’s disease

Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.

FDA approves sublingual apomorphine in off periods

22 de July de 2020

The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…

Posted in: Parkinson, Uncategorised

US authorizes an intranasal levodopa.

8 de April de 2020

An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….

Posted in: Parkinson

Levodopa infusion pump

2 de April de 2020

Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….

Posted in: Parkinson

Activation of phase I trial in Progressive Supranuclear Palsy

11 de March de 2020

Our Unit has achieved to be activated in this outstanding project and so serious pathology….

Posted in: Parkinson

We continue a phase I clinical trial in Parkinson

5 de March de 2020

We appreciate the great effort made by our patients to contribute to the development of…

Posted in: Parkinson

An amazing Phase I trial in Parkinson

9 de January de 2020

We have been activated in this trial that evaluates the safety of an innovative compound…

Posted in: Parkinson

Our clinical trials unit remains in prominent position

9 de January de 2020

We have reached the first position, in December 2019, in the international inclusion of patients…

Posted in: Alzeimer, News, Parkinson

Tavapadon (Cerevel): A very different dopamine agonist

29 de November de 2019

The UDIC has been selected to initiate a line of several clinical trials with this…

Posted in: Parkinson

Related Stories